On January 9, 2024, Guangshengtang issued the "Announcement on the Establishment of Holding Subsidiaries of Export Business and Related Party Transactions with Foreign Investment", stating that the company plans to jointly invest in the establishment of Guangfulai (Beijing) International Biotechnology with related parties with a registered capital of RMB 50 million, and the company intends to contribute 35 million yuan in monetary terms, accounting for 70% of the registered capital. The transaction constitutes a related party transaction, does not constitute a material asset restructuring, and does not need to be submitted to the general meeting of shareholders of the company for deliberation. The related party is Fuzhou Aotai Phase 9 Investment Partnership (Limited Partnership), with a capital contribution of RMB15 million, with Huang Fuhu as the executive partner. The new company has a manager, who is nominated by Party A.
Based on the company's strategic planning and business development needs, the investment purpose is to focus on expanding the international business field of the company's drugs, especially the anti-coronavirus drug Taizhongding, enhance the company's future growth potential, market competitiveness and profitability, meet the company's international strategic development needs, promote the development and growth of the company's international business scale, further enhance the company's comprehensive strength, and achieve the company's long-term strategic development goals.
Fujian Guangshengtang Pharmaceutical Co., Ltd. was listed on the Growth Enterprise Market of the Shenzhen Stock Exchange on April 22, 2015, and its main business is specialized in the research and development, production and sales of nucleoside anti-hepatitis B virus drugs. In the national economic industry, it belongs to the manufacturing industry and the pharmaceutical manufacturing industry; In terms of Shenwan industry classification, it belongs to the major category of pharmaceutical biology and the subcategory of chemical pharmaceuticals. As of October 25, 2023, the actual controllers of the company are Li Guoping, Ye Liqing, and Li Guodong.
As of 09/01/2024**, the company's share price is 2473 yuan shares, with a circulating market value of 335.2 billion yuan.
Announcement**: Disclaimer: This article is written by the robot, jointly incubated by Pencil Road and Hanxin Society, and the main data is provided by Hanguang Suwen. The content and data in this article are for reference only and do not constitute investment advice.